Cell therapies for chondral defects of the talus: a systematic review

Table 1 Generalities and patient baseline of the included studies

Author, year	Journal	Study Design	Follow-up (months)	Treatment	Procedures (n)	Female (%)	Mean age	Mean defect size (cm²)
Buda et al. [51]	Int Orthop	Retrospective	48.0	Control group (mACI)	40	37.5	31.4	1.7
Buda et al. [51]	Int Orthop	Retrospective	48.0	BMAC	40	32.5	30.2	1.8
Desando et al. [52]	Cartilage	Prospective	36.0	Control group (mACI)	7	42.9	31.2	1.8
Desando et al. [52]	Cartilage	Prospective	36.0	BMAC	15	33.3	31.0	1.8
Guney et al. [53]	Knee Surg Sports Traumatol Arthrosc	Prospective	47.3	Control group (MFX)	19	37.4	47, 4
			40.4	MFX & PRP	22	43.9	50.0
			30.1	Control group (Mosaicplasty)	13	37.6	15.4	> 0.2
Murphy et al. [54]	Knee Surg Sports Traumatol Arthrosc	Retrospective	36.7	MAST	38	31.2	35.0	1.7
Nguyen et al. [55]	Am J Sports Med	Retrospective	44.7	OAT & BMA, or PRGF	38	0.0	26.0	2.5
Richter et al. [56]	Foot Ankle Surg	Prospective	24.0	MAST & BMC	26	28.0	33.0	1.1
Richter et al. [57]	Foot Ankle Surg	Prospective	24.4	MAST & BMC	129	41.0	35.3	1.6
Richter et al. [57]	Foot Ankle Surg	Prospective	23.8	AMIC & PBC	129	40.0	35.6	1.8

BMC—bone marrow concentrate, PBC—peripheral blood concentrate, MAST—matrix-associated stem cell transplantation, AMIC—autologous matrix-induced chondrogenesis, PRP—platelet-rich plasma, mACI—membrane-assisted autologous chondrocyte implantation, PRGF—platelet-rich grow factors

ISSN: 1749-799X